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1. Introduction
Diabetes is of two types. Type 1 or insulin-dependent 
diabetes mellitus (IDDM) is basically due to autoimmune-
mediated destruction of the pancreatic β islets resulting in 
insulin defi ciency. Patients with type 1 diabetes usually have 
to take exogenous insulin for survival and to prevent the 
development of ketoacidosis. Type 2 diabetes or non-insulin 
dependent diabetes mellitus (NIDDM) is characterized by 
insulin resistance and is usually associated with abnormal 
insulin secretion. Globally, more than 90–95% of cases
of diabetes are of this kind, while type 1 accounts for only 
3–5% (Zimmet 1999; Zimmet et al 2001). The growing 
incidence of insulin resistance and type 2 diabetes is 
seriously threatening human health globally. At the dawn of 
the new millennium, when WHO announced that the world 
was facing an epidemic of type 2 diabetes, the major question 
that was confronting us is what really causes this insidious 
disease. 
This review deals with the mechanisms related to type 2 
diabetes. Numerous reports demonstrate that oversupply of 
lipids raises the circulating level of free fatty acid (FFA) and 
contributes to the development of type 2 diabetes (Boden 
1997; Mc Garry 2001. The excess FFA is ultimately stored 
in non-adipose depots leading to increased intramyocellular 
lipids, which cause insulin resistance (Boden et al 2001; 
Kuhlmann 2003). Initiation of insulin resistance or loss of 
insulin activity is the primary expression of this disease.
Although it is now fairly well established that FFAs are 
the major players effecting insulin resistance, the underlying 
mechanism by which this happens is still unclear. Inhibition 
of glucose transport by FFA has been found to be linked 
to insulin-mediated signals. Binding of insulin to the 
heterotetrameric membrane receptor results in insulin 
receptor substrate-1 (IRS-1) phosphorylation and IRS-1-
associated phosphatidylinositol 3 phosphate kinase (PI3 
kinase) activation (Dresner et al 1999; Yu et al 2002; Chavez 
et al 2003). This affects downstream effectors such as Akt/
Review
Molecular mechanism of insulin resistance
SAMIR BHATTACHARYA1,*, DEBLEENA DEY and SIB SANKAR ROY
Molecular Endocrinology Laboratory, Indian Institute of Chemical Biology, 4, Raja S C Mullick Road,
Kolkata 700032, India
1Cellular and Molecular Endocrinology Laboratory, Department of Zoology, School of Life Science, Visva-Bharati
(A Central University), Santiniketan 731 235, India
1Corresponding author (Fax. 91-3463-261268; Email, smrbhattacharya@yahoo.co.in)
Free fatty acids are known to play a key role in promoting loss of insulin sensitivity, thereby causing insulin resistance 
and type 2 diabetes. However, the underlying mechanism involved is still unclear. In searching for the cause of the 
mechanism, it has been found that palmitate inhibits insulin receptor (IR) gene expression, leading to a reduced 
amount of IR protein in insulin target cells. PDK1-independent phosphorylation of PKCε causes this reduction in 
insulin receptor gene expression. One of the pathways through which fatty acid can induce insulin resistance in insulin 
target cells is suggested by these studies. We provide an overview of this important area, emphasizing the current 
status. 
[Bhattacharya S, Dey D and Roy S S 2007 Molecular mechanism of insulin resistance; J. Biosci. 32 405–413]
Keywords. Fatty acid; insulin receptor; insulin resistance, insulin signalling; novel PKC; type 2 diabetes
http://www.ias.ac.in/jbiosci J. Biosci. 32(2), March 2007, 405–413, © Indian Academy of Sciences   4 5
Abbreviations used: IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin dependent diabetes mellitus; IR, insulin receptor; 
FFA, free fatty acid; IRS, insulin receptor substrate; PI3 kinase, phosphatidylinositol 3 phosphate kinase; PIP
2
,
 
phosphatidylinositol 4,5 
bisphosphate, DAG; diacylglycerol; PDK1, phosphoinositide-dependent kinase-1.
Samir Bhattacharya et al406
J. Biosci. 32(2), March 2007
PKB which activates the glucose transporter Glut4; Glut4 
is then translocated to the membrane and imports glucose 
into the cell (Kohn et al 1996; Tanti et al 1997; Hill et al 
1999). This suggests that the impairment of insulin activity 
leading to insulin resistance is linked to insulin signalling 
defects. Insulin signalling molecules involved in metabolic 
and mitogenic action may also play a role in cellular insulin 
resistance (Zick 2001; White 2002; Greene et al 2004). A 
few recent reports indicate that some PKC isoforms may 
have a regulatory effect on insulin signalling. The expression 
levels and activity of a few PKC isoforms are found to be 
associated with insulin resistance. Lipid infusion in rats 
and humans impairs insulin-stimulated glucose disposal
in muscle concomitantly with the activation of certain
PKC isoforms (Griffi n et al 1999; Yu et al 2002; Boden
and Shulman 2002). We have recently demonstrated that 
FFA-induced insulin resistance is linked to insulin receptor 
gene downregulation, in which a PKC isoform plays a 
signifi cant role (Dey et al 2005). Although much progress 
has been made in understanding the mechanism of FFA-
induced insulin resistance and type 2 diabetes, several 
lacunae exist in this important fi eld. In this review we briefl y 
describe these lacunae along with the current status of the 
problem.
2. Insulin receptor and signalling
The action of insulin is initiated through its binding with the 
target cell surface receptor that activates tyrosine kinase, a 
constituent of the receptor molecule. The insulin receptor 
(IR) is a heterotetramer consisting of two α subunits and 
two β subunits that are linked by disulphide bonds into an 
α
1
α
2 
and
 
β
1
β
2
 heterotetrameric complex. Insulin binds to the 
extracellular α subunit and transduces signals across the 
plasma membrane, which activates the intracellular tyrosine 
kinase C terminal domain of the β subunit. Binding of insulin 
to IR effects a series of intramolecular transphosphorylation 
reactions, where one β subunit phosphorylates its adjacent 
partner on a specifi c tyrosine residue (Pessin and Saltiel 
2000). Although IRs are present on the surface of virtually 
all cells, their expression in classical insulin target tissues, 
i.e. muscle, liver and fat, is extremely high (Brunetti et 
al 2001). However, there is very little information on the 
regulatory mechanism that controls the IR at the level of 
gene expression. Autophosphorylation of the IR tyrosine 
residue stimulates the catalytic activity of receptor tyrosine 
kinase which recruits IRS proteins (IRS-1 and IRS-2) (Rosen 
1987; Pessin and Saltiel 2000). These, in turn, augment the 
activity of the effector enzyme (Yenush et al 1998; White 
Figure 1.  Insulin signalling pathway showing binding of insulin with the IR leading to activation of Glut4 which imports glucose into 
the cell. Activated insulin receptor tyrosine kinase phosphorylates IRS and PI3 kinase. PI3 kinase produces PI4,5 P
2
 and PI3,4,5 P
3
. These 
serve as docking sites for two ser/thr kinase PH domains, i.e. PDK1 and Akt/PKB. Binding of Akt/PKB to PIP3 activates Glut4. Activated 
Glut4 is translocated to the plasma membrane to transport glucose into the cell.
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1998). PI3 kinase is a target of the IRS proteins (IRS-1 and 
IRS-2) which phosphorylates specifi c phosphoinositides 
to form phosphatidylinositol 4,5 bisphosphate (PIP
2
) 
to phosphatidylinositol 3,4,5 triphosphate; in turn, this 
activates ser/thr kinase, i.e. phosphoinositide-dependent 
kinase-1 (PDK1) (LeGood et al 1998). Activated PDK1 
phosphorylates or activates ser/thr kinase Akt/PKB. Akt 
contains a PH domain that also interacts directly with PIP3 
(Saltiel and Kahn 2001). Akt plays an important role by 
linking Glut4, the insulin-dependent glucose transporter 
protein, to the insulin signalling pathway. It activates Glut4 
which moves to the cell surface to transport glucose into the 
cell (Pessin et al 1999; Kupriyonova and Kendror 1999; 
Martin et al 2000). Figure 1 briefl y describes the insulin 
signalling pathway operative in the insulin target cell.
3. FFA-induced impairment of insulin signalling
Insulin has 3 major target tissues—skeletal muscle, adipose 
tissue and liver. Not only is the IR overexpressed in the cells 
of these tissues but these are also the three places where 
glucose is deposited and stored; no other cells can store 
glucose. In normal subjects the blood glucose level normally 
ranges between 90 and 120 mg/dl; after a meal this may go 
up to 250–300 mg/dl. The fasting insulin level remains at
15 µU/ml and after the intake of food it may go up to 40 µU/
ml. This increase in insulin secretion is responsible for the 
post-prandial decrease in glucose which reaches the normal 
level after about 2 hours. Removal of this excess glucose by 
insulin occurs due to glucose uptake and storage in insulin 
target cells such as skeletal muscle cells, hepatocytes and 
adipocytes. About 75% of this glucose is stored in skeletal 
muscle cells; therefore, it is the major target cell of insulin, 
while the rest is stored in the liver and adipocytes. When 
an increase in insulin after a meal cannot take care of this 
process, the higher glucose in the circulation remains for a 
longer period, as occurs in type 2 diabetes. Patients suffering 
from insulin resistance and type 2 diabetes frequently display 
signs of abnormal lipid metabolism, increased circulatory 
concentration and elevated deposition of lipids in the skeletal 
muscle (Boden 1997; Mc Garry 2001). Increase in plasma 
lipid levels impairs insulin activity, increase in plasma 
FFA reduces insulin-stimulated glucose uptake, whereas a 
decrease in lipid content improves insulin activity in the 
skeletal muscle cells, adipocytes and liver (Moller 2001). 
One of the sites that appears to be involved in fatty acid-
induced insulin resistance is the IR itself. There are different 
ways by which fatty acids could impose insulin resistance. 
These are changes in IR expression, binding of ligands, the 
phosphorylation state of its kinase domain and the activity 
of receptor tyrosine kinases could account for insulin 
resistance. It could be a functional defect or may be related 
to genetic defects in the IR that infl uences its expression, 
binding to ligands and tyrosine kinase activity (Pessin and 
Saltiel 2000). Interesting results are obtained by studying 
IRs in knockout mice. Homozygous IR-null mice die shortly 
after birth owing to extreme insulin resistance (Accili et al 
1996; Joshi et al 1996). IRS-1 is an important protein and 
homozygous knockout mice lacking a single allele of this 
gene lack any signifi cant phenotype, whereas homozygous 
disruption of the IRS-1 gene results in a mild form of insulin 
resistance (Araki et al 1994). IRS-1 homozygous null mice 
(IRS-1-/-) do not show a clear diabetic phenotypic expression, 
presumably because of pancreatic β cell compensation. 
However, mice that are doubly heterozygous (IR-/+, IRS-/+) 
develop both insulin resistance and diabetes (Bruning et al 
1997). Homozygous disruption of the IRS-2 gene, on the 
other hand, causes impairment of insulin secretion along 
with peripheral insulin resistance and diabetes (Withers et 
al 1998). The insulin resistance observed in IRS-2 knockout 
animals probably refl ects secondary events due to alteration 
in β cell function as IRS-2 appears to be unnecessary for 
insulin or exercise-stimulated glucose transport (Higaki
et al 1999). This observation is consistent with the results of 
studies in β cell-specifi c IR knockout mice, which develop 
peripheral insulin resistance and diabetes, most probably due 
to the changes in the pattern of insulin secretion (Kulkarni 
et al 1999).
FFA also affects downstream insulin signalling molecules. 
It inhibits insulin activation of IRS-1-associated PI3K 
activity in muscle. Reduction of insulin-stimulated IRS-1 
tyrosine phosphorylation and IRS-1-associated PI3K activity 
by FFA has been shown to be associated with an increase in 
IRS-1 serine phosphorylation. This in turn decreases IRS-1 
tyrosine phosphorylation, impairing down stream effectors 
(Yu et al 2002). FFA can disrupt further downstream insulin 
signals. Administration of saturated fat blocks insulin 
activation of Akt/PKB with a concomitant increase in the 
amount of ceramide and diacylglyerol in cultured muscle 
cells (Chavez et al 2003). Insulin actively sequesters Glut4 
at an intracellular location which increases the rate of Glut4 
traffi cking to the membrane (Martin et al 2000). Glut4 is the 
penultimate molecule in the signal and its translocation to 
the membrane by insulin is the ultimate step in signalling, as 
only then is glucose transported into the cell. Lipid-associated 
insulin resistance has also been shown to be linked to Glut4 
translocation defects (Pessin et al 1999). 
4. Mechanism of insulin resistance
From the above description it is clear that FFAs induce defects 
in the insulin signalling pathway. However, the underlying 
mechanism of FFA-induced impairment of insulin signals is 
still unclear. Does FFA cause a defect in the IR leading to 
reduced effi ciency in formation of the insulin–IR complex, 
or does it indirectly regulate IR activity which adversely 
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affects downstream signalling molecules? Is the effect 
of FFA localized to a number of signalling points? These 
questions have not been answered. It has been suggested 
that insulin signalling molecules involved in the metabolic 
action of insulin also play a role in cellular signalling (Zick 
2001; White 2002; Greene et al 2004). Some of the PKC 
isoforms represent such signalling molecules. PKC isoforms 
are classifi ed as classical (cPKCα, βI, βII, γ), novel (nPKC 
δ, ε, θ, η) and atypical (aPKC ζ, λ). cPKCs are activated by 
Ca+2 and diacylglycerol (DAG), nPKCs are activated by 
only DAG and aPKCs respond to neither Ca+2 nor DAG 
(Newton 2003). Among all these PKC isoforms, nPKCs are 
said to have a modulatory role in insulin signalling. Recent 
reports also demonstrate a link between nPKCs and FFA-
induced insulin resistance. Lipid infusion in rats and humans 
impaired insulin-stimulated glucose disposal into the muscle 
and concomitant activation of PKCθ and PKCδ (Boden and 
Shulman 2002; Itani et al 2002; Yu et al 2002). PKCδ has 
been shown to be a possible candidate for phosphorylation 
of the IR on serine residues, which obviously decreases 
tyrosine phosphorylation of the IR and affects its 
routing (Strack et al 1997). PKCδ has been shown to be 
regulating the state of IR phosphorylation (Kellerer 1997). 
Overexpression of PKCδ in cultured myotubes stimulates 
serine phosphorylation of the IR in response to insulin. Since 
tyrosine phosphorylation of IR is the requirement to initiate 
the insulin signal, phosphorylation of serine would reduce 
insulin signalling effi ciency. Overexpression of PKCδ in 
cultured myotubes stimulates serine phosphorylation of IR 
in response to insulin. Serine phosphorylation of IR changes 
IR distribution on the cell membrane; a rich component of it 
is localized on the internal membrane instead of extracellular 
domain thus causing attenuation of insulin-induced tyrosine 
phosphorylation of  the IR (Braiman et al 2001). These 
result in defects in the insulin signalling pathway imposing 
insulin resistance. Interestingly, activation of PKCδ and 
PKCθ occurs along with FFA-induced insulin resistance 
in muscle cells (Boden and Shulman 2002). Suppression 
of endogenous glucose production in the liver by insulin 
is effectively inhibited by FFA with concomitant activation 
of PKC. What is still not clear is the mechanism involved 
in PKCδ-mediated inhibition of IR activity and whether it 
is direct or indirect. One report demonstrated that PKCδ 
can directly inhibit IR kinase-stimulated IRS-1 associated 
tyrosine phosphorylation (Greene et al 2004). This has also 
been suggested to occur due to lipid-induced PKCθ activation 
in muscle (Schmitz-Peiffer et al 1997; Griffi n et al 1999). We 
have recently shown that PKCδ phosphorylation by insulin is 
further augmented by an FFA in 3T3L1 adipocyte cells and 
this is associated with the inhibition of insulin-stimulated 
IR β and IRS-1 tyrosine phosphorylation (Dey et al 2006). 
The results of these studies promise some understanding of 
the occurrence of FFA-induced insulin resistance. However, 
the precise pathway by which FFA induces impairment 
of signalling molecules leading to insulin resistance still 
remains unclear.
5. FFA-induced activation of PKCε is linked to 
inhibition of IR gene expression
Clearly, the IR is one of the major targets in FFA-induced 
impairment of insulin activity. It is true that the molecular 
mechanism of insulin resistance is suffi ciently complex. 
At the cellular level, it may occur at multiple steps of the 
insulin signalling pathway. Recent reports convincingly 
indicate that nPKCs, i.e. PKCδ, PKCθ and PKCε implement 
FFA-induced insulin resistance, which is closely associated 
with the attenuation of IR activity (Itani et al 2002; Boden 
and Shulman 2002; Greene et al 2004). However, a clear 
link between FFA-induced nPKC activation and impairment 
of the IR has not been demonstrated. Recent evidence has 
shown that PDK1 can directly phosphorylate all PKCs 
including nPKCs (Toker and Newton 2000). PDK1 is the 
key upstream kinase in the insulin signalling pathway and 
all PKCs and Akt activation are known to be dependent on it 
(Alessi et al 1997; Newton 2003). Phosphorylated Akt then 
activates Glut4, which moves to the membrane to import 
glucose. 
The PKCε isotype has recently been shown to be related 
to insulin resistance. Translocation of PKCε into the 
membrane is necessary for its phosphorylation by PDK1. 
PKCε is overexpressed in the skeletal muscle of diabetic 
animals and humans, and its association with the plasma 
membrane causes its activation. This overexpression and 
activation of PKCε leads to the downregulation of IR copy 
number on the cell membrane along with a decrease in Akt 
activity (Ikeda et al 2001; Itani et al 2002). Although these 
reports are interesting as they implicate a novel pathway of 
insulin resistance and diabetes, the underlying mechanism 
involved in PKCε-mediated insulin resistance has not 
yet been elucidated. We have recently shown a possible 
relationship between FFA-induced PKCε phosphorylation 
and concomitant downregulation of IR. To understand the 
mechanism, we selected adipocytes and skeletal muscle 
cells from rat as well as respective cell lines. We observed 
that insulin stimulation of PDK1 phosphorylation is 
inhibited by an FFA, i.e. palmitate. PKCε phosphorylation 
is dependent on PDK1; FFA incubation of skeletal muscle 
cells and adipocytes inhibited PDK1 phosphorylation but 
surprisingly increased PKCε phosphorylation. Inhibition 
of PDK1 by FFA is refl ected in Akt phosphorylation as 
Akt phosphorylation is also dependent on PDK1 (fi gure 2). 
These results are confl icting as FFA is expected to increase 
the DAG content in a cell, which would infl uence PKCε 
localization towards the cell membrane (Stahelin et al
2005) and PDK1 would phosphorylate PKCε since it is a 
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PDK1-dependent PKC isoform. This is the known pathway 
of nPKC phosphorylation by PDK1; on the contrary, PKCε 
showed PDK1-independent phosphorylation due to FFA 
(Dey et al 2005; Dey et al 2006). We could not understand 
how PDK1-independent phosphorylation of PKCε could 
occur due to FFA. This remained a mystery until we 
came across an interesting report describing constitutive 
phosphorylation of PKCε by FFA in a PDK1-independent 
manner. This report showed that myristic acid incubation of 
HEPG2 cells causes myristoylation of PKCε which results 
in constitutive phosphorylation of PKCε at thr566/ser729 
in the kinase domain required for PKCε activity. This 
phosphorylation was totally independent of PDK1, which 
the workers demonstrated by using PDK1 knockout cells. 
This PDK1-independent phosphorylation of PKCε could not 
be further increased by co-transfecting the PDK1 gene, or 
decreased with kinase-inactive PDK1 transfection (Cenni 
et al 2002). In the same way, addition of palmitate to skeletal 
muscle cells or adipocytes may affect palmitoylation of 
PKCε resulting in constitutive phosphorylation of PKCε 
(Dey et al 2005; Dey et al 2006). We also found that 
activation of PKCε is inversely related to IR gene expression, 
palmitate decreases IR mRNA in a time-dependent manner, 
while inhibitors of phosphoPKCε block this decrease. 
Palmitate activation of PKCε occurs at 2 h in the plasma 
membrane. At 6 h most of the phosphorylated PKCε is 
associated with the nuclear fraction indicating translocation 
of pPKCε from cytosol to the nuclear region. This appears 
to be related to the inhibition of IR gene transcription. 
Considerable inhibition of IR gene transcription occurs at 6 
h (Dey et al 2005). Taken together, it is clear that FFA causes 
PDK1-independent phosphorylation of PKCε which in turn 
translocates to the nucleus, and its time of entry into the 
nucleus coincides with inhibition of IR gene transcription. 
This would obviously reduce the copies of IR protein on the 
insulin target cell membrane. However, it is still unclear how 
pPKCε reduces IR gene expression on entering the nucleus.
6. Molecular mechanism of FFA-induced inhibition
of IR gene transcription
The IR is usually expressed at low levels in all cell types except 
in classical insulin target tissues, i.e. skeletal muscle, liver 
and fat, where IR is expressed at a very high level (Goldfi ne 
1987). Many workers have suspected that the IR is the major 
Figure 2.  Effect of FFA on insulin-stimulated downstream signal, PDK1, Akt and PKCε. Skeletal muscle cells were treated without or 
with palmitate for 8 h and insulin was added to both control (I) and palmitate (I+P) incubated cells. Cells without any of the treatments were 
taken as control (C). On termination of incubation, cells were lysed by sonication and 50 µg protein from each cell lysate was resolved in 
10% SDS-PAGE and then subjected to Western blot analysis with anti-pPDK1, pAkt/Akt or anti-pPKCε antibodies (1:1000). (Dey et al 
2005).
pAkt /Akt
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component responsible for the loss of insulin sensitivity or 
insulin resistance. A few earlier reports indicate that the IR 
is of major importance in certain states of insulin resistance 
in humans, where qualitative and quantitative abnormalities 
of the receptor may cause defects in transmembrane 
signalling (Taylor 1992; Polonsky et al 1996; Taylor 1999; 
Virkamaki et al 1999). However, very little is known about 
the regulatory mechanism controlling gene expression of the 
IR. To understand the molecular basis of regulation of IR 
gene expression, the promoter region of the human IR gene 
has been identifi ed and studied by several groups (Mitchell 
and Tjian 1989; Seino et al 1989; Lee et al 1992). The IR 
promoter region extends over 1800 bases upstream from the 
IR gene ATG codon and is extremely GC rich. It contains a 
series of GGGCGG repeats that are putative binding sites for 
the mammalian transcription factor SP1 (Mitchell and Tjian 
1989). It lacks a TATA box or consensus initiator sequence 
and includes multiple transcription initiator sites within the 
fi rst 300 bp GC-rich region. Two unique AT-rich sequences, 
C2 and E3, within the IR gene promoter have been identifi ed 
and both these sequences are positively regulated by the 
architectural transcription factor HMGA1 (earlier known 
as HMG1-Y), a member of the high mobility group protein 
family (Brunetti et al 2001). HMGA1 interacts with the AT-
rich regions in the minor groove of DNA through highly 
conserved DNA-binding peptide motifs termed AT hooks, 
and regulates transcriptional activation of many genes by 
modifying DNA conformation, which permits recruitment 
of transcriptional factor to the transcription start site (Bustin 
and Reeves 1996; Reeves 2001). HMGA1 protein has 
the ability to bind to DNA packaged in nucleosomes and 
regulates the expression of a number of genes through their 
migration from the heterochromatin to euchromatin region 
(Reeves et al 2000; Reeves 2001; Reeves and Beckerbauer 
2001). It has been shown that inhibition of HMGA1 in cells 
that naturally express high IR levels signifi cantly reduces 
cell surface expression of IR. Inversely, cells with relatively 
low IR content, when transfected with HMGA1, show IR 
overexpression and a signifi cant increases in IR protein 
expression (Brunetti et al 2001). All these indicate that 
HMGA1 plays an important role in regulating transcription 
of the IR gene. The same group of workers has recently 
Figure 3. Schematic representation of the mechanism involved in insulin resistance. Excess of lipid mobilization to the major insulin 
target cells effects constitutive phosphorylation of PKCε, and that translocates to the nuclear region and reduces IR promoter activation. 
Inhibition in HMGA1 gene expression restricts recruitment of SP1 and CEBPβ to the IR promoter causing inhibition of promoter activation 
leading to downregulation of insulin receptor gene expression.
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shown that HMGA1 induces transcriptional activation 
of the human IR gene by permitting the recruitment of 
SP1 and cEBPβ, the ubiquitously expressed transcription 
factors, to the promoter region. HMGA1 plays the role 
of an architectural transcription factor here as mutational 
interference of the HMGA1 binding site in the IR promoter 
abolished its binding, which adversely affected recruitment 
of SP1 and cEBPβ to the IR promoter, resulting in inhibition 
of IR promoter activation (Foti et al 2003).
A recent report demonstrates that a genetic fl aw which 
reduces the intracellular expression of HMGA1 protein 
can adversely affect IR expression in cells and tissues 
from subjects with insulin resistance and type 2 diabetes 
(Foti et al 2005). There could be another aspect in the 
regulation of IR gene expression involving HMGA1. We 
have demonstrated that FFA-induced downregulation of the 
IR gene is associated with PDK1-independent constitutive 
phosphorylation of PKCε in major insulin target cells. 
Phospho PKCε is translocated to the nucleus which causes 
inhibition of IR gene expression. But how phosphorylated 
PKCε (pPKCε) downregulates the IR gene is unclear. Further 
work using PKC inhibitors showed that their administration 
along with FFA could block inhibition of IR gene expression 
(Dey et al 2005; Dey et al 2006). The question is how is 
pPKCε related to the regulation of IR gene expression. There 
is a possibility that activated PKCε phosphorylates HMGA1 
which inhibits HMGA1 mobilization to the promoter 
region IR gene. It has been shown that phosphorylation of 
HMGA1 protein reduces its DNA-binding ability (Reeves 
and Beckerbauer 2001). Phosphorylated HMGA1 protein 
would preferentially interact with positively charged 
histones as there would be an additional negative charge, 
while dephosphorylated HMGA1 proteins are expected to 
interact with negatively charged DNA (Harrer et al 2004). 
Since HMGA1 proteins are highly mobile and this mobility 
is fi nely tuned, hyper- and hypophosphorylation of these 
could be the major factors in regulating the expression of 
the IR gene. Without the mobilization of HMGA1 to the IR 
promoter there is no recruitment of transcription factor to the 
promoter region of the IR gene and therefore no expression 
of the IR gene.
Although it is well established that FFA is responsible 
for insulin resistance as its increase in the milieu of major 
insulin-sensitive cells causes insulin resistance by reducing 
insulin sensitivity, the molecular mechanism involved is 
largely unknown. This review focuses on the current trends 
in research in this important domain and throws light on 
certain possibilities regarding the manner in which FFA 
inhibits insulin activity. The available information suggests 
that the IR is one of the most important sites identifi ed so 
far for loss of insulin sensitivity. Figure 3 schematically 
represents the present status of knowledge in this fi eld. 
Excess of lipid mobilization to the major insulin target cells 
will effect constitutive phosphorylation of PKCε, which 
when translocated to the nuclear region somehow reduces IR 
promoter activation. Inhibition of HMGA1 gene expression 
in diabetic patients has recently been demonstrated, but how 
this is linked to FFA is unclear. However, there may be a 
possibility that FFA-induced pPKCε might play a role in this 
particular area.
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